治疗药物-话题@MedSci

#治疗药物#

300篇内容 | 2619人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1921791, encodeId=542a1921e912a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=JAMA超详细综述：盘点COVID-19的治疗药物及临床试验进展, objectType=article, longId=192707, objectId=71d3192e07c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71d3192e07c6, replyNumber=0, likeNumber=77, createdTime=2020-12-27, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71d3192e07c6, moduleTitle=JAMA超详细综述：盘点COVID-19的治疗药物及临床试验进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71d3192e07c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921818, encodeId=f38519218184a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Lancet子刊：国内创新药哌罗替尼有望成为HER2阳性乳腺癌替代治疗药物, objectType=article, longId=207595, objectId=f31120e5958c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31120e5958c, replyNumber=0, likeNumber=71, createdTime=2021-12-09, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31120e5958c, moduleTitle=Lancet子刊：国内创新药哌罗替尼有望成为HER2阳性乳腺癌替代治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31120e5958c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921810, encodeId=00f819218100b, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=未来可期！获得FDA批准的埃博拉治疗药物，银马泽伯来了！, objectType=article, longId=202205, objectId=61fc202205f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61fc202205f0, replyNumber=0, likeNumber=30, createdTime=2021-08-05, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61fc202205f0, moduleTitle=未来可期！获得FDA批准的埃博拉治疗药物，银马泽伯来了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61fc202205f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921805, encodeId=fde419218055c, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=全球硬皮病相关间质性肺疾病靶向治疗药物在华上市，可延缓肺部疾病进展, objectType=article, longId=200335, objectId=dbe02003355f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbe02003355f, replyNumber=0, likeNumber=98, createdTime=2021-06-10, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbe02003355f, moduleTitle=全球硬皮病相关间质性肺疾病靶向治疗药物在华上市，可延缓肺部疾病进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbe02003355f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921790, encodeId=e33c1921e90c5, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=**胆管癌靶向治疗药物获得美国FDA批准！, objectType=article, longId=192585, objectId=36c019258504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c019258504, replyNumber=0, likeNumber=71, createdTime=2021-02-21, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c019258504, moduleTitle=**胆管癌靶向治疗药物获得美国FDA批准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c019258504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921783, encodeId=657a1921e83c6, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=中国胃癌免疫治疗药物欧狄沃®获批，生存期显著延长, objectType=article, longId=189951, objectId=cadc189951ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cadc189951ee, replyNumber=0, likeNumber=84, createdTime=2020-07-17, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cadc189951ee, moduleTitle=中国胃癌免疫治疗药物欧狄沃®获批，生存期显著延长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cadc189951ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921781, encodeId=ed6c1921e8140, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=糖尿病周围神经病变的治疗药物与联合用药, objectType=article, longId=188524, objectId=ab001885240e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab001885240e, replyNumber=0, likeNumber=86, createdTime=2020-06-03, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab001885240e, moduleTitle=糖尿病周围神经病变的治疗药物与联合用药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab001885240e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921784, encodeId=5e2d1921e84d5, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=CLIN CHEM LAB MED：β-内酰胺类抗生素结果的测量不确定度：对治疗药物监测的估计和临床影响, objectType=article, longId=190210, objectId=1e9c19021073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e9c19021073, replyNumber=0, likeNumber=66, createdTime=2020-12-05, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e9c19021073, moduleTitle=CLIN CHEM LAB MED：β-内酰胺类抗生素结果的测量不确定度：对治疗药物监测的估计和临床影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e9c19021073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921817, encodeId=735a192181ead, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=EMBO Rep：FGF21变异体有望成为新一代糖尿病治疗药物, objectType=article, longId=205279, objectId=f2b52052e923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2b52052e923, replyNumber=0, likeNumber=87, createdTime=2021-09-28, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2b52052e923, moduleTitle=EMBO Rep：FGF21变异体有望成为新一代糖尿病治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2b52052e923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921793, encodeId=79931921e93e7, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=瑞德西韦获批成日本国内**新冠治疗药物，优先用于重症患者, objectType=article, longId=193829, objectId=333719382925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=333719382925, replyNumber=0, likeNumber=68, createdTime=2020-11-01, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=333719382925, moduleTitle=瑞德西韦获批成日本国内**新冠治疗药物，优先用于重症患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=333719382925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921812, encodeId=d32519218129e, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Leber遗传性视神经病变基因治疗药物LUMEVOQ提交上市许可申请, objectType=article, longId=204052, objectId=97b620405294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97b620405294, replyNumber=0, likeNumber=73, createdTime=2021-07-27, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97b620405294, moduleTitle=Leber遗传性视神经病变基因治疗药物LUMEVOQ提交上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97b620405294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921794, encodeId=5f8f1921e9495, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=NMPA：多发性硬化的S1P靶向治疗药物西尼莫德批准上市, objectType=article, longId=194138, objectId=e8bf19413837, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8bf19413837, replyNumber=0, likeNumber=78, createdTime=2021-04-09, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8bf19413837, moduleTitle=NMPA：多发性硬化的S1P靶向治疗药物西尼莫德批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8bf19413837)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921803, encodeId=18451921803e3, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Nat Commun ：COVID-19治疗新希望，猫类冠状病毒的治疗药物，竟能有效抑制新冠病毒复制！, objectType=article, longId=200197, objectId=46d620019ed4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46d620019ed4, replyNumber=0, likeNumber=71, createdTime=2021-06-13, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46d620019ed4, moduleTitle=Nat Commun ：COVID-19治疗新希望，猫类冠状病毒的治疗药物，竟能有效抑制新冠病毒复制！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46d620019ed4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921788, encodeId=b3881921e88d3, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, objectType=article, longId=191689, objectId=a505191689b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a505191689b3, replyNumber=0, likeNumber=57, createdTime=2021-03-09, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a505191689b3, moduleTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a505191689b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921808, encodeId=78e1192180801, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Regeneron的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, objectType=article, longId=202130, objectId=a6d020213007, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6d020213007, replyNumber=0, likeNumber=60, createdTime=2020-11-02, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6d020213007, moduleTitle=Regeneron的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6d020213007)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921802, encodeId=3947192180257, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Lancet HIV:广泛耐药性艾滋病毒株出现，多种治疗药物均无效, objectType=article, longId=199665, objectId=f0c719966533, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0c719966533, replyNumber=0, likeNumber=0, createdTime=2020-10-08, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0c719966533, moduleTitle=Lancet HIV:广泛耐药性艾滋病毒株出现，多种治疗药物均无效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0c719966533)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921799, encodeId=7b3c1921e999e, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=FDA批准长链脂肪酸氧化代谢病的最佳治疗药物——Dojolvi, objectType=article, longId=197031, objectId=57f219e03170, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57f219e03170, replyNumber=0, likeNumber=72, createdTime=2021-01-22, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57f219e03170, moduleTitle=FDA批准长链脂肪酸氧化代谢病的最佳治疗药物——Dojolvi, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57f219e03170)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921804, encodeId=77d51921804e9, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Cell Death Dis：萝卜种子提取物Sulforaphene或可成为食道癌的新治疗药物, objectType=article, longId=200292, objectId=d6cc20029239, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6cc20029239, replyNumber=0, likeNumber=73, createdTime=2020-09-05, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6cc20029239, moduleTitle=Cell Death Dis：萝卜种子提取物Sulforaphene或可成为食道癌的新治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6cc20029239)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921785, encodeId=092e1921e8525, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑, objectType=article, longId=190912, objectId=52ec19091290, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52ec19091290, replyNumber=0, likeNumber=72, createdTime=2020-04-06, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52ec19091290, moduleTitle=刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52ec19091290)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921768, encodeId=7f3d1921e685f, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Celgene的Reblozyl成为美国针对β地中海贫血的治疗药物, objectType=article, longId=182744, objectId=f017182e4470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f017182e4470, replyNumber=0, likeNumber=71, createdTime=2020-05-02, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f017182e4470, moduleTitle=Celgene的Reblozyl成为美国针对β地中海贫血的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f017182e4470)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

治疗药物

2020-05-29

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

JAMA超详细综述：盘点COVID-19的治疗药物及临床试验进展

2020-12-27

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Lancet子刊：国内创新药哌罗替尼有望成为HER2阳性乳腺癌替代治疗药物

2021-12-09

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

未来可期！获得FDA批准的埃博拉治疗药物，银马泽伯来了！

2021-08-05

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

全球硬皮病相关间质性肺疾病靶向治疗药物在华上市，可延缓肺部疾病进展

2021-06-10

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

**胆管癌靶向治疗药物获得美国FDA批准！

2021-02-21

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

中国胃癌免疫治疗药物欧狄沃®获批，生存期显著延长

2020-07-17

仁者大医 (审核中...)

前往app查看评论内容

#治疗药物#

糖尿病周围神经病变的治疗药物与联合用药

2020-06-03

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

CLIN CHEM LAB MED：β-内酰胺类抗生素结果的测量不确定度：对治疗药物监测的估计和临床影响

2020-12-05

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

EMBO Rep：FGF21变异体有望成为新一代糖尿病治疗药物

2021-09-28

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

瑞德西韦获批成日本国内**新冠治疗药物，优先用于重症患者

2020-11-01

仁心济世 (审核中...)

前往app查看评论内容

#治疗药物#

Leber遗传性视神经病变基因治疗药物LUMEVOQ提交上市许可申请

2021-07-27

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

NMPA：多发性硬化的S1P靶向治疗药物西尼莫德批准上市

2021-04-09

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Nat Commun ：COVID-19治疗新希望，猫类冠状病毒的治疗药物，竟能有效抑制新冠病毒复制！

2021-06-13

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物

2021-03-09

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Regeneron的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物

2020-11-02

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Lancet HIV:广泛耐药性艾滋病毒株出现，多种治疗药物均无效

2020-10-08

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

FDA批准长链脂肪酸氧化代谢病的最佳治疗药物——Dojolvi

2021-01-22

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Cell Death Dis：萝卜种子提取物Sulforaphene或可成为食道癌的新治疗药物

2020-09-05

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑

2020-04-06

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Celgene的Reblozyl成为美国针对β地中海贫血的治疗药物

2020-05-02

科室
- - 订阅+
  - 更多科室
工具
服务